Date: November 16, 2020
Time: 7:00am PDT
So far, it has been estimated that 2 billion individuals have been infected by hepatitis B virus (HBV). Among them, 250 million have developed a chronic infection and are at risk to develop cirrhosis and hepatocellular carcinoma. Every year, 1 million individuals die for these end-stage liver diseases. Nevertheless, these numbers are considered an underestimation and this is mainly due to the lack of adequate HBV screening programmes. Despite the availability of an effective vaccine, chronic HBV infection still remains an important driver of hepatocarcinogenesis. In endemic areas for HBV, 70-80% cases of liver cancer are caused by this virus.
In this light, the availability of an accurate armamentarium of HBV biomarkers is crucial for a proper diagnosis of HBV infection and in turn for a prompt retention in care of HBV infected patients pivotal slow down disease progression.
In this light, this webinar will be aimed at strengthening the importance of a proper and timely diagnosis of HBV infection, and at highlighting the role of classical and innovative biomarkers (such as quantitative serum HBsAg and quantitative serum HBeAg) in optimizing the management of patients with HBV infection.
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.